Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab

Rachel E. Sanborn, See all authors in comments

Research output: Other contribution

Original language	American English
State	Published - Nov 8 2022

Name	Articles, Abstracts, and Reports

Access to Document

@misc{2a9b108c4cc349eeb7d63e6ed122e2cb,

title = "Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab",

author = "Sanborn, {Rachel E.} and comments, {See all authors in}",

year = "2022",

month = nov,

day = "8",

language = "American English",

series = "Articles, Abstracts, and Reports",

type = "Other",

}